Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Novas-E
- Development stage
- Phase 4
- Lead developer
- Maks Drug
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Novas-E** is a marketed delayed-release fixed-dose oral tablet from Maks Drug containing naproxen 500 mg and esomeprazole 20 mg. It combines naproxen, a nonsteroidal anti-inflammatory drug that suppresses prostaglandin synthesis to relieve pain and inflammation, with esomeprazole, a proton-pump inhibitor that reduces gastric acid secretion and helps lower the risk of NSAID-associated gastric ulcers. The formulation releases esomeprazole immediately before delayed release of enteric-coated naproxen in the small intestine. It is indicated for osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients requiring NSAID therapy who are at risk of gastric ulcers. ([mdl.com.bd](https://www.mdl.com.bd/product/detail/view/3))
- Brand names
- Novas-E
- Other names
- naproxen + esomeprazole
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on Novas-E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Novas-E.